阿仑膦酸钠引发食管炎的探讨  

Relationship clinical research between esophagitis and alendronate treatment on postmenopausal osteoporosis

作　　者：史丽萍[1] 吴友伟[1] 邢坤[1] 张健[1] 周健[1] 

机构地区：[1]陕西省人民医院老年消化科,西安710068

出　　处：《中国临床保健杂志》2013年第2期131-132,I0001,共3页Chinese Journal of Clinical Healthcare

基　　金：陕西省科技厅社发公关项目(2007K15-05)

摘　　要：目的探讨绝经后妇女口服阿仑膦酸钠引发食管炎对患者耐受性的影响。方法采用临床配对平行对照研究。计划入组病例60例,评估后,入选患者均经胃镜检查,经配对分入试验组或对照组。试验治疗疗程为12个月,在治疗前、6个月末和12个月末对阿仑膦酸钠引发食管炎的安全性进行评估。结果治疗后骨密度明显上升,阿仑膦酸钠组与碳酸钙组比较差异有统计学意义(P<0.01)。食管炎的发生率两组差异无统计学意义(碳酸钙组:14.17%、阿仑膦酸钠组:15.83%)。结论阿仑膦酸钠在增加骨密度、减少骨折的同时,并无增加食管炎甚至食管溃疡的风险。Objective To investigate incidence of esophagitis and other side effect of alendronate in the treatment on postmenopausal osteoporosis. Methods The clinical paired parallel controlled study included 60 cases which were treatment divided into group and control group after diagnosed by gastroscopy, there was significant differ- ence in age, body weight, bone mineral density and the endoscopic manifestations in two groups. The study duration was 12 months. We assessed the esophagitis induced by alendronate at three point （prion to treatment, 6 months and 12 months ）. Results After alendronate treatment, the bone mineral density increased significantly （P 〈 0.01 ）. The inci- dence of was not significantly different esophagitis in two groups （calcium carbonate group： 14. 17%, alendronate group ： 15.83% ）. Conclusion Alendronate increase bone mineral density without significant adverse reactions.

关 键 词：骨质疏松 绝经后 食管炎 二磷酸盐类 碳酸钙 

分 类 号：R595.3[医药卫生—内科学]